Laboratorio de Biotecnología Molecular, Instituto de Biotecnología Misiones (InBioMis), Facultad de Ciencias Exactas Químicas y Naturales (FCEQyN), Universidad Nacional de Misiones (UNaM), Ruta Nacional N°12 Km 7.5, Miguel Lanús, 3304 Posadas, Misiones, Argentina.
Laboratorio de Genética Hematológica, IMEX, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina; Miller School of Medicine, University of Miami, Miami, FL, United States.
Gene. 2019 Apr 30;694:71-75. doi: 10.1016/j.gene.2019.01.038. Epub 2019 Feb 7.
The BCR-ABL1 oncogene is associated with chronic myeloid leukemia (CML) pathogenesis, but the molecular mechanisms that initiate leukemogenesis are still unclear. Cancer pathogenesis has been associated with genetic alterations that may lead to inactivation of tumor suppressor genes. Phosphatase and tensin homolog (PTEN) is frequently deleted or inactivated in various tumors. A recently discovered variant of PTEN, PTEN-Long (PTEN-L), results from an alternative translation initiation site located upstream of the canonic AUG and generates a protein of 576 amino acids instead the expected protein of 403 amino acids. A 16 bp perfect palindromic motif centered on the PTEN-L CUG start codon is required for translation initiation. A single nucleotide polymorphism (SNP) of PTEN-L gene rs12573787 is located on the first exon respect to the CUG initiation site. In this case-control study we evaluated the association of genetic variants in PTEN-L with CML risk and therapy response in the Argentine population. The allele A of SNP rs12573787 was found to be associated with CML risk OR (95% CI) 1.71 (1.11-2.63) p = 0.016, which resulted consistent by multivariate analysis adjusted by gender and age. According to previous evidence that CML is more frequent in males, we found that the genetic risk of CML was confined to this gender. Unexpectedly, we also found this association confined to CML patients older than 45 years old. To our knowledge, this is the first time that PTEN-L rs1257378 was studied in CML suggesting that the variant A allele is a risk factor for CML development but, no association with the failure to TKIs treatment was found.
BCR-ABL1 癌基因与慢性髓性白血病(CML)的发病机制有关,但导致白血病发生的分子机制仍不清楚。癌症的发病机制与可能导致肿瘤抑制基因失活的遗传改变有关。磷酸酶和张力蛋白同源物(PTEN)在各种肿瘤中经常缺失或失活。PTEN 的一种新发现的变体,PTEN-Long(PTEN-L),源自位于经典 AUG 上游的另一个翻译起始位点,产生一个 576 个氨基酸的蛋白质,而不是预期的 403 个氨基酸的蛋白质。位于 PTEN-L CUG 起始密码子中心的 16 个碱基对的完美回文基序是翻译起始所必需的。PTEN-L 基因 rs12573787 的单核苷酸多态性(SNP)位于第一个外显子,相对于 CUG 起始位点。在这项病例对照研究中,我们评估了阿根廷人群中 PTEN-L 基因遗传变异与 CML 风险和治疗反应的关系。SNP rs12573787 的等位基因 A 与 CML 风险 OR(95%CI)1.71(1.11-2.63)p=0.016 相关,多变量分析调整性别和年龄后结果一致。根据先前 CML 在男性中更为常见的证据,我们发现 CML 的遗传风险仅限于男性。出乎意料的是,我们还发现这种关联仅限于年龄大于 45 岁的 CML 患者。据我们所知,这是首次在 CML 中研究 PTEN-L rs1257378,表明变体 A 等位基因是 CML 发展的危险因素,但未发现与 TKI 治疗失败相关。